What is the typical CJC-1295 + Ipamorelin dosage?

Published protocols describe 200–600 mcg total per dose, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of CJC-1295 + Ipamorelin?

Risks noted for CJC-1295 + Ipamorelin include water retention, tingling, and headache. Tell your provider about your medications and conditions before starting.

How long do the peptides in CJC-1295 + Ipamorelin last in the body?

The reported half-life is ~30 min (CJC) / ~2 h (ipamorelin). Onset is typically reported at 1–2 weeks (sleep); 6–12 weeks (composition).

How should CJC-1295 + Ipamorelin be stored?

Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

GROWTH · PEPTIDE BLEND

What is CJC-1295 + Ipamorelin?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

CJC-1295 with ipamorelin is a combination of two growth hormone secretagogues. CJC-1295 mimics growth hormone-releasing hormone and ipamorelin mimics ghrelin, so together they signal the pituitary through two receptors to release more of the body’s own growth hormone.

CJC-1295 + Ipamorelin at a glance

Type: Peptide blend
Also known as: CJC/Ipa, CJC-1295 with ipamorelin
Mechanism: GHRH analog + selective GHRP (two-receptor GH pulse)
Status: Compounded (Rx)
Half-life: ~30 min (CJC) / ~2 h (ipamorelin)
Route: Subcutaneous
Dosing range in the literature: 200–600 mcg total per dose
Onset: 1–2 weeks (sleep); 6–12 weeks (composition)
Storage: Refrigerated (2–8 °C); use within the pharmacy beyond-use date

How CJC-1295 + Ipamorelin works

The pituitary releases growth hormone in pulses. A GHRH analog increases how much is released per pulse, and a ghrelin-receptor agonist amplifies the pulse. Used together they produce a larger release than either alone.

What CJC-1295 + Ipamorelin is studied for

Growth hormone release
Sleep quality
Recovery
Body composition

Each component reliably raises growth hormone and IGF-1 in human studies. Evidence that the combination improves body composition, sleep or recovery comes mainly from clinical practice, not controlled trials.

Being studied for something is not proof that it works. Results in individuals vary.

CJC-1295 + Ipamorelin dosing

Published protocols describe 200–600 mcg total per dose, once nightly (up to 3× daily), given subcutaneous. Onset is typically reported at 1–2 weeks (sleep); 6–12 weeks (composition).

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

CJC-1295 + Ipamorelin dosage calculator →

CJC-1295 + Ipamorelin side effects and risks

Water retention
Tingling
Headache

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is CJC-1295 + Ipamorelin FDA approved?

Neither component is FDA-approved.

Approval and trial status change. This page was last reviewed on October 1, 2026.

CJC-1295 + Ipamorelin at G1 Peptides

G1 Peptides supplies CJC-1295 + Ipamorelin as vials (5/5 mg, 10/10 mg) and in pens (Apex, Apex Plus, Trinity Stack, Fragment Apex, Lean Recovery). Prescription products ship only after a licensed provider has reviewed the order.

Shop CJC-1295 + Ipamorelin →

CJC-1295 + Ipamorelin questions

What is CJC-1295 + Ipamorelin?: CJC-1295 with ipamorelin is a combination of two growth hormone secretagogues. CJC-1295 mimics growth hormone-releasing hormone and ipamorelin mimics ghrelin, so together they signal the pituitary through two receptors to release more of the body’s own growth hormone.
What is CJC-1295 + Ipamorelin used for?: CJC-1295 + Ipamorelin is studied for growth hormone release, sleep quality, recovery, and body composition. Each component reliably raises growth hormone and IGF-1 in human studies. Evidence that the combination improves body composition, sleep or recovery comes mainly from clinical practice, not controlled trials.
How does CJC-1295 + Ipamorelin work?: The pituitary releases growth hormone in pulses. A GHRH analog increases how much is released per pulse, and a ghrelin-receptor agonist amplifies the pulse. Used together they produce a larger release than either alone.
Is CJC-1295 + Ipamorelin FDA approved?: Neither component is FDA-approved.
What is the typical CJC-1295 + Ipamorelin dosage?: Published protocols describe 200–600 mcg total per dose, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of CJC-1295 + Ipamorelin?: Risks noted for CJC-1295 + Ipamorelin include water retention, tingling, and headache. Tell your provider about your medications and conditions before starting.
How long do the peptides in CJC-1295 + Ipamorelin last in the body?: The reported half-life is ~30 min (CJC) / ~2 h (ipamorelin). Onset is typically reported at 1–2 weeks (sleep); 6–12 weeks (composition).
How should CJC-1295 + Ipamorelin be stored?: Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.